Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeoVax Labs, Inc.GOVX · Entity 8419 | Director | June 17, 2026 | June 22, 2026 |
| InMed Pharmaceuticals Inc.INM · Entity 8139 | Director | December 19, 2025 | December 19, 2025 |
| MEDICINOVA INCMNOV · Entity 7011 | Director | June 23, 2026 | June 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeoVax Labs, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-06-17 | Direct | 6,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 6,000 · Balance 6,000 |
InMed Pharmaceuticals Inc.
Report date December 19, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-12-18 | Direct | 2,725 |
Reported balance
After 2025-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 1,750 · Balance 2,725 F1: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner.
MEDICINOVA INC
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.36 · Expires 2036-06-22 | Direct | 44,500 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 44,500 · Balance 44,500 F1: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 25, 2026 20:35 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 44,500 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001683168-26-005110 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 44,500 shares Expires 2036-06-22 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027, subject to continued service with the Company. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:20 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 6,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001437749-26-021320 · rdgdoc.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2036-06-17 Read SEC document |
| December 19, 2025 Filed Dec 19, 2025 16:42 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,750 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001213900-25-123637 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Common shares · 1,750 shares Expires 2030-12-18 F1 · derivative.exercise_date: The options were granted on 12/19/2025 and will vest 100% on the one-year anniversary of the grant date (December 18, 2026) or immediately prior to the next Annual General Meeting, whichever is sooner. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:11 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001683168-25-004649 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-16 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2025, December 31,2025, March 31,2026 and June 30,2026, subject to continued service with the Company. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 13:51 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001437749-25-019644 · rdgdoc.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-01-02 F1 · date: This stock option was granted on January 2, 2025, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of the GeoVax Labs, Inc. 2025 Stock Incentive Plan. Such approval occurred on June 5, 2025, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:51 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 24,500 | $0.00 Strike: $1.84 | $0.00 |
DisclosureSEC source: 0001683168-25-001046 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2035-02-11 F1 · derivative.exercise_date: The option vests in four equal installments on May 12, 2025, August 12, 2025, November 12,2025 and February 12, 2026, subject to continued service with the Company. Read SEC document |
| December 20, 2024 Filed Dec 23, 2024 14:25 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001213900-24-111566 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 975 Underlying: Common shares · 550 shares Expires 2029-12-19 F1 · derivative.exercise_date: The options were granted on 12/20/2024 and will vest 100% on the one-year anniversary of the grant date (December 19, 2025) or immediately prior to the next Annual General Meeting, whichever is sooner. F2 · balance_after: On November 14, 2024, the common stock of InMed was reverse split on a 1-for-20 basis. This number reflects that reverse stock split. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:07 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 8,050 | $0.00 Strike: $2.17 | $0.00 |
DisclosureSEC source: 0001437749-24-026791 · rdgdoc.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,050 Underlying: Common Stock · 8,050 shares Expires 2034-08-12 Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 23:40 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001683168-24-004155 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2024, December 31, 2024, March 31, 2025 and June 30, 2025, subject to continued service with the Company. Read SEC document |
| December 23, 2023 Filed Dec 26, 2023 18:09 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,100 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001213900-23-098495 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common shares · 7,100 shares Expires 2028-12-22 F1 · derivative.exercise_date: The options were granted on 12/23/2023 and will vest 100% on the one-year anniversary of the grant date (December 23, 2024) or immediately prior to the next Annual General Meeting, whichever is sooner. Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:18 UTC | MEDICINOVA INC MNOV · Entity 7011 | GrantStock Option (Right to Buy) · Derivative | 18,333 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001683168-23-005416 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,333 Underlying: Common Stock · 18,333 shares Expires 2033-08-03 F1 · derivative.exercise_date: The option vests in four equal installments on September 30, 2023, December 31, 2023, March 31, 2024 and June 30, 2024, subject to continued service with the Company. Read SEC document |
| August 01, 2023 Filed Aug 14, 2023 20:52 UTC | GeoVax Labs, Inc. GOVX · Entity 8419 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.76 | $0.00 |
DisclosureSEC source: 0001437749-23-023741 · rdgdoc.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-12-07 F1 · date: This stock option was granted on December 7, 2022, with the exercise price set based on the closing price of the underlying common stock as of that date. The stock option was granted contingent upon stockholder approval of an increase in common shares reserved for the company's stock incentive plan. Such approval occurred on August 1, 2023, so that is the date upon which the stock option is deemed granted pursuant to SEC reporting guidance. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 22:08 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 840 | $0.00 Strike: $1.78 | $0.00 |
DisclosureSEC source: 0001213900-22-080987 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Common shares · 840 shares Expires 2027-12-15 F1 · derivative.exercise_date: The options were granted on 12/16/2022 and will vest as follows: Vesting 100% on the one-year anniversary of the grant date (Dec 16, 2023) or immediately prior to the next AGM, whichever is sooner. F2 · balance_after: On September 7, 2022, the common stock of InMed was reverse split on a 1-for-25 basis. This number reflects that reverse stock split. Read SEC document |
| August 10, 2022 Filed Aug 11, 2022 00:14 UTC | InMed Pharmaceuticals Inc. INM · Entity 8139 | GrantEmployee Stock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001213900-22-046530 · ownership.xml · derivative · entry 1 Lemerond Nicole · CIK 0001941712 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common shares · 14,000 shares Expires 2027-08-10 F1 · derivative.exercise_date: The options were granted on Aug 10, 2022 and will vest monthly, in arrears, as follows: (i) 390 stock options will vest on the 10th day of each month for 35 months, and (ii) 350 stock options will vest on Aug 10, 2025 (the three year anniversary of Grant date). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.